These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

96 related articles for article (PubMed ID: 13458924)

  • 1. [Insulin and glucagon activity of pancreas extracts from dogs treated by BZ-55].
    STAHL J; DORNER M
    Ann Endocrinol (Paris); 1957; 18(2):258-9. PubMed ID: 13458924
    [No Abstract]   [Full Text] [Related]  

  • 2. [Effect of N1-sulfanilylo-N2-n-butylcarbamide on course of alloxan diabetes in rabbits and on hyperglycemic factor (glucagon) in pancreatic extracts in dogs].
    CZYZYK A
    Pol Arch Med Wewn; 1957; 27(8):1057-67. PubMed ID: 13505313
    [No Abstract]   [Full Text] [Related]  

  • 3. SEPARATION OF HUMAN INSULIN, GLUCAGON AND OTHER PANCREATIC PROTEINS.
    LOCHNERJDE V; ESTERHUIZEN AC; UNGER RH
    Diabetes; 1964; 13():387-94. PubMed ID: 14210684
    [No Abstract]   [Full Text] [Related]  

  • 4. Evidence for the presence of glucagon-like immunoreactivity (GLI) in the pancreas.
    Srikant CB; Unger RH
    Endocrinology; 1976 Dec; 99(6):1655-8. PubMed ID: 1001259
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Role of the liver and of the pancreas in hypoglycemic effect of oral antidiabetics (BZ-55 and D-860)].
    MOSINGER B; BRAUN T; WENKEOVA J; KUJALOVA V
    Cesk Fysiol; 1959 Apr; 8(3):225. PubMed ID: 13671564
    [No Abstract]   [Full Text] [Related]  

  • 6. The effect of derivatives of IPTD on blood sugar and glucagon content of pancreas.
    ITO Y; MORIWAKI C; UI M; GOMI Y; WAKABAYASHI K; TAKATORI K; YAMADA Y; ASANO S
    Endocrinol Jpn; 1960 Dec; 7():347-52. PubMed ID: 13718125
    [No Abstract]   [Full Text] [Related]  

  • 7. [Comparative evaluation of the effect of diaboral and insulin on the secretory function of the pancreas in dogs under normal conditions and in alloxan diabetes].
    Rudyĭ RV
    Farmakol Toksikol; 1968; 31(1):80-3. PubMed ID: 5675356
    [No Abstract]   [Full Text] [Related]  

  • 8. Paradoxical reduction in pancreatic glucagon with normalization of somatostatin and decrease in insulin in normoglycemic alloxan-diabetic dogs: a putative mechanism of glucagon irresponsiveness to hypoglycemia.
    Rastogi KS; Lickley L; Jokay M; Efendic S; Vranic M
    Endocrinology; 1990 Feb; 126(2):1096-104. PubMed ID: 1967577
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Behavior and metabolic significance of plasma free fatty acids after total pancreatectomy].
    Siri G
    Chir Ital; 1965 Dec; 17(6):685-93. PubMed ID: 5181132
    [No Abstract]   [Full Text] [Related]  

  • 10. [Insular cytology and insulin formation in the rat after an exogenous administration of lipocaic, vagotonin and glucagon].
    THERET C
    Ann Endocrinol (Paris); 1962; 23():394-402. PubMed ID: 13980883
    [No Abstract]   [Full Text] [Related]  

  • 11. The effects of insulin, glucagon, glutamate, and glucose infusion on blood glutamate and plasma glucose levels in naive rats.
    Zlotnik A; Gruenbaum BF; Klin Y; Gruenbaum SE; Ohayon S; Sheiner E; Kuts R; Boyko M; Bichovsky Y; Shapira Y; Teichberg VI
    J Neurosurg Anesthesiol; 2011 Oct; 23(4):323-8. PubMed ID: 21836527
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Somatostatin and pancreatic polypeptide secretion: effects of glucagon, insulin, and arginine.
    Weir GC; Samols E; Loo S; Patel YC; Gabbay KH
    Diabetes; 1979 Jan; 28(1):35-40. PubMed ID: 759249
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Antidiabetic action of hypoglycemic sulfonamides in the dog deprived of 9/10 of his pancreas].
    LOUBATIERES A; SASSINE A; MARIANI MM; FRUTEAU DE LACLOS C
    C R Seances Soc Biol Fil; 1960; 154():1475-8. PubMed ID: 13763659
    [No Abstract]   [Full Text] [Related]  

  • 14. Inhibition of glucagon secretion.
    Young A
    Adv Pharmacol; 2005; 52():151-71. PubMed ID: 16492545
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effects of glucagon, insulin, amylin and CGRP on feeding.
    Geary N
    Neuropeptides; 1999 Oct; 33(5):400-5. PubMed ID: 10657517
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Maximal stimulation of pancreatic islet B-cells, and A-cell response to arginine, in dogs with longterm pancreatic acinar atrophy.
    Meister R; Berger I; Schwille PO; Gebhardt C
    Eur J Surg; 1991 May; 157(5):333-40. PubMed ID: 1678647
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The potentiation of exogenous insulin by tolbutamide in depancreatized dogs.
    CAREN R; CORBO L
    J Clin Invest; 1957 Nov; 36(11):1546-50. PubMed ID: 13475492
    [No Abstract]   [Full Text] [Related]  

  • 18. The clinical response and the amount of insulin extractable from the pancreas in diabetic patients treated with oral hypoglycaemic drugs: a report on five cases.
    BOGOCH A; DAVIS TW; JOW E; WRENSHALL GA
    Can Med Assoc J; 1959 Sep; 81(5):347-56. PubMed ID: 13802132
    [No Abstract]   [Full Text] [Related]  

  • 19. Persistent pancreatic glucagon but not insulin response to arginine in pancreatectomized dogs.
    Mashiter K; Harding PE; Chou M; Mashiter GD; Stout J; Diamond D; Field JB
    Endocrinology; 1975 Mar; 96(3):678-93. PubMed ID: 1116479
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Antidiabetic activity of a highly potent and selective nonpeptide somatostatin receptor subtype-2 agonist.
    Strowski MZ; Cashen DE; Birzin ET; Yang L; Singh V; Jacks TM; Nowak KW; Rohrer SP; Patchett AA; Smith RG; Schaeffer JM
    Endocrinology; 2006 Oct; 147(10):4664-73. PubMed ID: 16857751
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.